Massive Market Opportunity

How big is the biotechnology market?

According to Precedence Research, the global biotechnology market is projected to grow from $1.3 trillion in 2023 to $3.2 trillion by 2030.

Biotech
$3.2 trillion

How big is the cancer drug development market?

According to Fortune Business Insights, the global oncology drugs market is projected to grow from $205 billion in 2023 to $484 billion by 2030.

Cancer
$484 billion
CancerVax

redefining
immunotherapy

Pre-clinical. We’re developing cutting edge immunotherapy cancer treatments that use the body’s immune system to fight cancer.

Development Partners

Development Partners

With more than 500 physicians and scientists working at the forefront of cancer discoveries, the UCLA Health Jonsson Comprehensive Cancer Center is a leader in providing both experimental and traditional cancer treatments. Working with a team of world-class cancer researchers and practicing oncologists at UCLA, CancerVax began the initial development of its novel Universal Cancer Treatment platform. Also working with CancerVax, UCLA developed a promising cancer drug candidate – a single-disease specific immunotherapy targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults.

Development Partners

Flashpoint was founded on nanotechnology developed over the past 10 years in the laboratory of Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University and 2024 winner of the prestigious Kavli Prize in Nanoscience. Flashpoint’s groundbreaking nanotechnology discovery platform enables the development of therapeutic candidates with superior product profiles. Validated in numerous in-vivo models, this technology has transformed components that are ineffective in conventional formulations into curative cancer immunotherapies. CancerVax is working with Flashpoint to deliver its novel Universal Cancer Treatment therapies using Flashpoint’s nanoparticle technology.

News Highlights

August 29, 2024

Cancervax Taps Flashpoint Therapeutics’ Nanotechnology Platform to Drive Universal Cancer Treatment

Cancervax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, today announced that the Company has entered into a research agreement with Flashpoint Therapeutics to perform research on its newly patent-pending Universal Cancer Treatment platform.

August 27, 2024

Cancervax Files New Patent for Its Novel Universal Cancer Treatment Platform

Cancervax, Inc., the developer of a breakthrough universal cancer treatment platform that will use the body’s immune system to fight cancer, today announced that the Company has recently filed a new patent application which includes a Smart mRNA Technology. mRNA, short for messenger RNA, is the underlying technology that made the COVID-19 vaccine so effective and inexpensive.

August 1, 2024

Cancervax Adds Key Members to Its Research Team

Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that the Company has added two key members to its cancer research team. Dr. Jonathan Lakey will serve as Chief Scientific Advisor and Dr. Adam Grant will serve as Principal Scientist.

May 21, 2024

Cancervax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Treatment Targeting Milestone

Cancervax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNP) using “click chemistry,” for targeting cancer cells.